تداخلات سيرترالين

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Sertraline hydrochloride capsules are contraindicated in patients: Taking, or within 14 days of stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7.1 )] . (نشرة سيرترالين، موانع الاستعمال)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة البلادونا والأفيون، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة أمفيتامين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (نشرة أمفيتامين وديكستروأمفيتامين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (نشرة أوكسيكودون، التداخلات الدوائية)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة أوكسيمورفون، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة أوليسيريدين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to increased risk of bleeding. (نشرة إيدوكسابان، التداخلات الدوائية)

Sertraline hydrochloride capsules are contraindicated in patients: Taking, or within 14 days of stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7.1 )] . (نشرة سيرترالين، موانع الاستعمال)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة باراسيتامول وكودايين، الاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة بنتازوسين ونالوكسون، الاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوبرينورفين، التداخلات الدوائية)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة بوبرينورفين ونالوكسون، التداخلات الدوائية)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وباراسيتامول وكافيين وكودايين، التداخلات الدوائية)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة بوتورفانول، الاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Taking pimozide [see Drug Interactions ( 7.1 )] . (نشرة سيرترالين، موانع الاستعمال)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Sertraline hydrochloride capsules are contraindicated in patients: Taking, or within 14 days of stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7.1 )] . (نشرة سيرترالين، موانع الاستعمال)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonergic Drugs The concomitant use of dextroamphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. (نشرة ديكستروأمفيتامين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Sertraline hydrochloride capsules are contraindicated in patients: Taking, or within 14 days of stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7.1 )] . (نشرة سيرترالين، موانع الاستعمال)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة ريميفنتانيل، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Sertraline hydrochloride capsules are contraindicated in patients: Taking, or within 14 days of stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7.1 )] . (نشرة سيرترالين، موانع الاستعمال)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

THESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE. (نشرة فلومازينيل، تحذير مؤطر)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة فنتانيل، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Sertraline hydrochloride capsules are contraindicated in patients: Taking, or within 14 days of stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7.1 )] . (نشرة سيرترالين، موانع الاستعمال)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (نشرة كاربامازيبين، موانع الاستعمال)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة كودايين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

LOREEV XR should not be used in such patients without adequate antidepressant therapy. (نشرة لورازيبام، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة ليسديكسامفيتامين، التحذيرات والاحتياطات)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة ليفورفانول، الاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Sertraline hydrochloride capsules are contraindicated in patients: Taking, or within 14 days of stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7.1 )] . (نشرة سيرترالين، موانع الاستعمال)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة مورفين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (نشرة ميتاكسالون، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة ميثامفيتامين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

الجمع بين نبتة سانت جون ومضادات الاكتئاب والأدوية السيروتونينية الأخرى يزيد خطر متلازمة السيروتونين. (NCCIH, St. John's Wort)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة سيرترالين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون، التداخلات الدوائية)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة هيدروكودون وإيبوبروفين، الاحتياطات)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة هيدروكودون وباراسيتامول، الاحتياطات)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون وكلورفينيرامين، التداخلات الدوائية)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون وهوماتروبين، التداخلات الدوائية)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدرومورفون، التداخلات الدوائية)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Monoamine Oxidase Inhibitors or Tricyclic Antidepressants Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents because the action of albuterol sulfate on the cardiovascular… (نشرة إبراتروبيوم وسالبوتامول، التداخلات الدوائية)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

• Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (نشرة أدرينالين، التداخلات الدوائية)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. (نشرة أرتيكايين وأدرينالين، التداخلات الدوائية)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة سيرترالين، التحذيرات والاحتياطات)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (نشرة أرفورموتيرول، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (نشرة إسزوبيكلون، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs) e.g., paroxetine Tricyclic Antidepressants (TCAs) e.g., amitriptyline desipramine imipramine nortriptyline bupropion trazodone ↑ SSRIs (except sertraline) ↑ TCAs ↑ trazodone Careful dosage titration of the antidepressant and monitoring for antidepressant response are recommended when coadministered… (نشرة إلفيتيغرافير وكوبيسيستات وإمتريسيتابين وتينوفوفير، التداخلات الدوائية)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

The concurrent use of Xyrem with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and… (نشرة أوكسيبات الصوديوم، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة أوميكليدينيوم وفيلانتيرول، التداخلات الدوائية)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions. (نشرة إيتراكونازول، التداخلات الدوائية)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (نشرة إيزوبرينالين، التداخلات الدوائية)

Increases in sertraline dosage should be guided by clinical response. (نشرة إيفافيرينز، التداخلات الدوائية)

Sertraline ↓ sertraline Increases in sertraline dosage should be guided by clinical response. (نشرة إيفافيرينز ولاميفودين وتينوفوفير، التداخلات الدوائية)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Drugs that inhibit these CYP pathways (such as desipramine, paroxetine, ritonavir, sertraline for CYP2D6; ketoconazole, erythromycin, saquinavir, and grapefruit juice for CYP3A4; and amiodarone and tobacco smoke for CYP1A2) can be expected to cause increased plasma levels of propafenone. (نشرة بروبافينون، التحذيرات والاحتياطات)

…Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (نشرة بريلوكايين وأدرينالين، التداخلات الدوائية)

Caution is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (نشرة بريمونيدين، التداخلات الدوائية)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (نشرة بريمونيدين وتيمولول، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة سيرترالين، التحذيرات والاحتياطات)

Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). (نشرة بوبروبيون، التداخلات الدوائية)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (نشرة بوبيفاكايين، التحذيرات والاحتياطات)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (نشرة بوبيفاكايين وأدرينالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة سيرترالين، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة بوديزونيد وفورموتيرول، التداخلات الدوائية)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (نشرة تيربوتالين، الاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

The CNS depressant effects of Zanaflex with alcohol and other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants) may be additive [see Drug Interactions ( 7.4 )] . (نشرة تيزانيدين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

The benzodiazepines, including temazepam, produce additive CNS-depressant effects when co-administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. (نشرة تيمازيبام، التداخلات الدوائية)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Antidepressants : Selective Serotonin Reuptake Inhibitors (SSRIs): paroxetine, sertraline ↓ paroxetine ↓ sertraline If either sertraline or paroxetine is initiated in patients receiving PREZISTA/ritonavir, dose titrating the SSRI based on a clinical assessment of antidepressant response is recommended. (نشرة دارونافير، التداخلات الدوائية)

Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs): e.g. paroxetine, sertraline SSRIs: effects unknown When co-administering with SSRIs, TCAs, or trazodone, careful dose titration of the antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitoring for antidepressant response are recommended. (نشرة دارونافير وكوبيسيستات، التداخلات الدوائية)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (نشرة داريدوريكسانت، التحذيرات والاحتياطات)

Caution should be taken when darifenacin extended-release tablets is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants ( 7.2 ) (نشرة داريفيناسين، التداخلات الدوائية)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (نشرة درونابينول، التحذيرات والاحتياطات)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (نشرة دورزولاميد وتيمولول، التداخلات الدوائية)

…be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of Valium, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. (نشرة ديازيبام، التداخلات الدوائية)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة سيرترالين، التحذيرات والاحتياطات)

…that may Increase Risk of Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin… (نشرة ديسموبريسين، التداخلات الدوائية)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (نشرة ديسيكلومين، التداخلات الدوائية)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Antidepressants: nefazodone, selective serotonin reuptake inhibitors (SSRIs): e.g. fluoxetine, paroxetine, tricyclics: e.g. amitriptyline, nortriptyline ↑ antidepressants A dose decrease may be needed for these drugs when co-administered with ritonavir. (نشرة ريتونافير، التداخلات الدوائية)

…levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (نشرة ريفابنتين، التداخلات الدوائية)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

…5-HT 3 Receptor Antagonists Ondansetron Decrease exposure Statins Metabolized by CYP3A4 Simvastatin Decrease exposure Thiazolidinediones Rosiglitazone Decrease AUC by 66% Tricyclic Antidepressants Nortriptyline A tuberculosis treatment regimen including rifampin (600 mg/day), isoniazid (300 mg/day), pyrazinamide (500 mg 3× per day), and pyridoxine (25 mg) was… (نشرة ريفامبيسين، التداخلات الدوائية)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (نشرة زاليبلون، التحذيرات)

Sertraline Concomitant administration of zolpidem and sertraline increases exposure to zolpidem [see Clinical Pharmacology (12.3) ] . (نشرة زولبيديم، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة سالبوتامول، التداخلات الدوائية)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة سالميتيرول، التداخلات الدوائية)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Concomitant use of other drugs that cause central nervous system (CNS) adverse reactions (e.g., alcohol, sedatives, hypnotics, opiates, and anxiolytics) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may increase this effect [see Drug Interactions ( 7.1 )] . (نشرة سكوبولامين، التحذيرات والاحتياطات)

The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. (نشرة سلفاميثوكسازول وتريميثوبريم، التداخلات الدوائية)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (نشرة سوفوريكسانت، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

…apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline, and metronidazole, thereby delaying elimination and increasing blood levels of these drugs. (نشرة سيميتيدين، التداخلات الدوائية)

Dose adjustments may be required for concomitant medications that are predominantly metabolized by CYP2D6 (e.g., desipramine, metoprolol, and carvedilol) and particularly those with a narrow therapeutic index (e.g., flecainide and most tricyclic antidepressants) [see Clinical Pharmacology ( 12.3 )] . (نشرة سيناكالسيت، التداخلات الدوائية)

Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (نشرة غليكوبيرولات، التداخلات الدوائية)

Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (نشرة غيفيتينيب، التداخلات الدوائية)

Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (نشرة فازوبريسين، التداخلات الدوائية)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

• MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system. (نشرة فورموتيرول، التداخلات الدوائية)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Antidepressant: Paroxetine, trazodone ↓ Paroxetine Any paroxetine dose adjustment should be guided by clinical effect (tolerability and efficacy). ↑ Trazodone Adverse events of nausea, dizziness, hypotension, and syncope have been observed following coadministration of trazodone and ritonavir. (نشرة فوسامبرينافير، التداخلات الدوائية)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval, such as class IA or class III antiarrhythmic medications, tricyclic antidepressants, macrolides, and antipsychotics [see Warnings and Precautions ( 5.2 )] . (نشرة فوسفومايسين، التداخلات الدوائية)

Other Corticosteroids, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D Drugs whose level is decreased by phenytoin Anticoagulants Apixaban, dabigatran, edoxaban, rivaroxaban Antiepileptic drugs The effect of phenytoin on phenobarbital, valproic acid and sodium valproate serum levels… (نشرة فوسفينيتوين، التداخلات الدوائية)

…prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic antidepressants, and certain macrolides and fluoroquinolones. (نشرة فوسكارنت، التداخلات الدوائية)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Acute cardiac arrest may be possible during treatment with tricyclic antidepressants; therefore, Anticholium should only be considered as an antidote for this indication while the patient has continuous ECG monitoring. (نشرة فيزوستيغمين، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة سيرترالين، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة سيرترالين، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Sertraline hydrochloride capsules may increase phenytoin concentrations. (نشرة سيرترالين، التداخلات الدوائية)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (نشرة فينيليفرين، التداخلات الدوائية)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (نشرة كاربيدوبا وليفودوبا وإنتاكابون، التداخلات الدوائية)

Since the sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously. (نشرة كاريزوبرودول، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (نشرة كلورازيبات، التداخلات الدوائية)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (نشرة كلوروبروكايين، الاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

…Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (نشرة كلونازيبام، التداخلات الدوائية)

Tricyclic antidepressants Clinical Implication Concomitant use of tricyclic antidepressants with clonidine can increase blood pressure and may counteract the hypotensive effects of clonidine. (نشرة كلونيدين، التداخلات الدوائية)

Sympathomimetics, postganglionic blocking agents, and tricyclic antidepressants: Concomitant administration may increase the risk of cardiovascular adverse reactions. (نشرة كوكايين، التداخلات الدوائية)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Antidepressant: bupropion ↓ bupropion ↓ active metabolite, hydroxybupropion Patients receiving KALETRA and bupropion concurrently should be monitored for an adequate clinical response to bupropion. (نشرة لوبينافير وريتونافير، التداخلات الدوائية)

Activation of Mania/Hypomania Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. (نشرة لوراسيدون، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (نشرة ليدوكايين، التداخلات الدوائية)

…Adverse Reactions Due to Drug Interactions with FLAVALTA Risk of Severe, Persistent Hypertension Due to Drug Interactions Between FLAVALTA and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of FLAVALTA (containing a vasoconstrictor, epinephrine) in patients receiving monoamine oxidase inhibitors (MAOI), or tricyclic antidepressants may result… (نشرة ليدوكايين وأدرينالين، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Administration of sertraline in patients stabilized on levothyroxine may result in increased levothyroxine requirements. (نشرة ليفوثيروكسين، التداخلات الدوائية)

Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants : May potentiate effect of albuterol on the cardiovascular system. (نشرة ليفوسالبوتامول، التداخلات الدوائية)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (نشرة ليمبوريكسانت، التحذيرات والاحتياطات)

Administration of sertraline in patients stabilized on liothyronine sodium may result in increased liothyronine sodium requirements. (نشرة ليوثيرونين، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة سيرترالين، التحذيرات والاحتياطات)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (نشرة ميبيفاكايين، التحذيرات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. (نشرة ميثسكوبولامين، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (نشرة سيرترالين، التحذيرات والاحتياطات)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (نشرة ميفلوكين، التداخلات الدوائية)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (نشرة نالبوفين، التداخلات الدوائية)

Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of antidepressants, (e.g., selective serotonin reuptake inhibitors and many tricyclics), antipsychotics (e.g., haloperidol, risperidone and thioridazine), beta-blockers (e.g., metoprolol) and Type 1C antiarrhythmics (e.g., propafenone and flecainide). (نشرة نالتريكسون وبوبروبيون، التداخلات الدوائية)

Antidepressants bupropion ↓ bupropion and active metabolite hydroxy-bupropion Monitor for an adequate clinical response to bupropion. trazodone ↑ trazodone Adverse reactions of nausea, dizziness, hypotension, and syncope have been observed following co-administration of trazodone and ritonavir. (نشرة نيرماتريلفير وريتونافير، التداخلات الدوائية)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (نشرة سيرترالين، التحذيرات والاحتياطات)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (نشرة سيرترالين، التحذيرات والاحتياطات)

For patients taking warfarin, carefully monitor the international normalized ratio. (نشرة سيرترالين، التحذيرات والاحتياطات)

Drugs Metabolized by CYP2D6 Clinical Impact: Sertraline hydrochloride capsules are a CYP2D6 inhibitor [see Clinical Pharmacology ( 12.3 )] . (نشرة سيرترالين، التداخلات الدوائية)

Antidepressants: tricyclic antidepressants ↑ tricyclic antidepressants Coadministration with REYATAZ has the potential to produce serious and/or life-threatening adverse events and has not been studied. (نشرة أتازانافير، التداخلات الدوائية)

False-Positive Effects on Screening Tests for Benzodiazepines False-positive urine immunoassay screening tests for benzodiazepines have been reported in patients taking another sertraline hydrochloride product. (نشرة سيرترالين، التحذيرات والاحتياطات)

False-Positive Effects on Screening Tests for Benzodiazepines False-positive urine immunoassay screening tests for benzodiazepines have been reported in patients taking another sertraline hydrochloride product. (نشرة سيرترالين، التحذيرات والاحتياطات)

False-Positive Effects on Screening Tests for Benzodiazepines False-positive urine immunoassay screening tests for benzodiazepines have been reported in patients taking another sertraline hydrochloride product. (نشرة سيرترالين، التحذيرات والاحتياطات)

Other Serotonergic Drugs Clinical Impact: Concomitant use of sertraline hydrochloride capsules with other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (نشرة سيرترالين، التداخلات الدوائية)

Drugs Metabolized by CYP2D6 Clinical Impact: Sertraline hydrochloride capsules are a CYP2D6 inhibitor [see Clinical Pharmacology ( 12.3 )] . (نشرة سيرترالين، التداخلات الدوائية)

Other Serotonergic Drugs Clinical Impact: Concomitant use of sertraline hydrochloride capsules with other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (نشرة سيرترالين، التداخلات الدوائية)

Drugs Metabolized by CYP2D6 Clinical Impact: Sertraline hydrochloride capsules are a CYP2D6 inhibitor [see Clinical Pharmacology ( 12.3 )] . (نشرة سيرترالين، التداخلات الدوائية)

Antidepressants: The hypotensive effect of MAO inhibitors or tricyclic antidepressants may be exacerbated when administered with beta-blockers. (نشرة بروبرانولول، التداخلات الدوائية)

However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (نشرة بريكسبيبرازول، التحذيرات والاحتياطات)

Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants. (نشرة بنزتروبين، التحذيرات)

Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (نشرة بيرفينازين، التداخلات الدوائية)

False-Positive Effects on Screening Tests for Benzodiazepines False-positive urine immunoassay screening tests for benzodiazepines have been reported in patients taking another sertraline hydrochloride product. (نشرة سيرترالين، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

It is difficult to determine if Tolcapone tablets played a role in the pathogenesis of these events because these patients received several concomitant medications affecting the central nervous system such as monoaminergic (i.e., MAO-I, tricyclic and selective serotonin reuptake inhibitors) and anticholinergic agents. (نشرة تولكابون، الاحتياطات)

In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (نشرة تياغابين، التحذيرات)

Drugs Metabolized by CYP2D6 Clinical Impact: Sertraline hydrochloride capsules are a CYP2D6 inhibitor [see Clinical Pharmacology ( 12.3 )] . (نشرة سيرترالين، التداخلات الدوائية)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (نشرة حمض الفالبرويك، التداخلات الدوائية)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (نشرة ديفالبروكس (فالبروات)، التداخلات الدوائية)

Drugs Metabolized by CYP2D6 Clinical Impact: Sertraline hydrochloride capsules are a CYP2D6 inhibitor [see Clinical Pharmacology ( 12.3 )] . (نشرة سيرترالين، التداخلات الدوائية)

Drugs Metabolized by CYP2D6 Clinical Impact: Sertraline hydrochloride capsules are a CYP2D6 inhibitor [see Clinical Pharmacology ( 12.3 )] . (نشرة سيرترالين، التداخلات الدوائية)

There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations. (نشرة كاربيدوبا، التداخلات الدوائية)

…placebo-controlled trials of adult patients with major depressive disorder, the proportion of patients with shifts in fasting glucose from normal (<100 mg/dL) to high (≥126 mg/dL) was greatest in the VRAYLAR 3 mg per day + antidepressant therapy arm (3.2%) compared with those taking VRAYLAR 1.5 mg per day + antidepressant therapy (2%) or those placebo-treated (1.3%). (نشرة كاريبرازين، التحذيرات والاحتياطات)

False-Positive Effects on Screening Tests for Benzodiazepines False-positive urine immunoassay screening tests for benzodiazepines have been reported in patients taking another sertraline hydrochloride product. (نشرة سيرترالين، التحذيرات والاحتياطات)

False-Positive Effects on Screening Tests for Benzodiazepines False-positive urine immunoassay screening tests for benzodiazepines have been reported in patients taking another sertraline hydrochloride product. (نشرة سيرترالين، التحذيرات والاحتياطات)

False-Positive Effects on Screening Tests for Benzodiazepines False-positive urine immunoassay screening tests for benzodiazepines have been reported in patients taking another sertraline hydrochloride product. (نشرة سيرترالين، التحذيرات والاحتياطات)

These include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or cobicistat-containing products. (نشرة لوفاستاتين، التحذيرات)

These included patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and in patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs. (نشرة ليوبروليد، التحذيرات والاحتياطات)

False-Positive Effects on Screening Tests for Benzodiazepines False-positive urine immunoassay screening tests for benzodiazepines have been reported in patients taking another sertraline hydrochloride product. (نشرة سيرترالين، التحذيرات والاحتياطات)

Drugs Metabolized by CYP2D6 Clinical Impact: Sertraline hydrochloride capsules are a CYP2D6 inhibitor [see Clinical Pharmacology ( 12.3 )] . (نشرة سيرترالين، التداخلات الدوائية)

Additionally, no dosage adjustment is required for diazepam, lithium, atenolol, tolbutamide, digoxin, and drugs metabolized by CYP3A4, when sertraline hydrochloride capsules is administered concomitantly [see Clinical Pharmacology ( 12.3 )] . (نشرة سيرترالين، التداخلات الدوائية)

Additionally, no dosage adjustment is necessary for valproate, lithium, lamotrigine, lorazepam, or sertraline when coadministered with ABILIFY MAINTENA. [See Clinical Pharmacology (12.3) ] . (نشرة أريبيبرازول، التداخلات الدوائية)

No clinically significant drug interactions have been either observed or are expected when DESCOVY is combined with the following drugs: buprenorphine, itraconazole, ketoconazole, lorazepam, methadone, midazolam, naloxone, norbuprenorphine, norgestimate/ethinyl estradiol, and sertraline. (نشرة إمتريسيتابين وتينوفوفير، التداخلات الدوائية)

No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa and dopa-decarboxylase inhibitor. (نشرة إنتاكابون، الاحتياطات)

Additionally, no dosage adjustment is required for diazepam, lithium, atenolol, tolbutamide, digoxin, and drugs metabolized by CYP3A4, when sertraline hydrochloride capsules is administered concomitantly [see Clinical Pharmacology ( 12.3 )] . (نشرة سيرترالين، التداخلات الدوائية)

…changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .] 7.2 Fluoxetine In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes… (نشرة ديسلوراتادين، التداخلات الدوائية)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (نشرة روبينيرول، التداخلات الدوائية)